Zika Virus, IgM Antibody Capture ELISA, Serum

Clinical Use

Use

This test is useful for screening for the presence of IgM-class antibodies to Zika virus. It is important in the context of symptomatic patients who have had potential exposure to Zika virus, especially when testing occurs at least 2 weeks post-symptom onset or post-exposure. This test is an initial step in diagnosing potential Zika virus infection, though confirmatory testing is often necessary due to the possibility of false-positive and false-negative results.

Special Instructions

Not provided.

Limitations

A presumptive positive result only suggests infection with Zika virus and is not confirmatory. False-positive results may occur in patients with other flavivirus infections or post-vaccination against yellow fever. Negative results cannot rule out infection if tested prior to antibody development. Asymptomatic pregnant women with Zika virus exposure should not be tested using this assay due to seropersistence of IgM-class antibodies, which can persist for months and complicate the distinction between recent and past infections.

Test Details

FDA Approved